Biomay Secures FDA Approval for Cas9 Nuclease Manufacturing at Headquarters Location

Biomay AG Receives FDA Approval for Manufacturing and Supply of Recombinant Cas9 Nuclease Vienna, Austria – Biomay AG, a privately owned Contract Development and Manufacturing Organization (CDMO), announced today that it has successfully obtained approval from the U.S. Food and Drug Administration (FDA) for the manufacturing, testing, and release of recombinant Cas9 nuclease from its headquarters…

Source